https://www.selleckchem.com/pr....oducts/abbv-cls-484.
th a hazard ratio (HR) of 1.350 (95%CI 1.190-1.531, P0.001). Patients receiving both EGFR-TKIs and once-daily TRT were more likely to develop symptomatic RP than patients receiving concurrent chemoradiotherapy. The ilV30, tlV20, and comorbidity of COPD may predict the risk of symptomatic RP among NSCLC patients receiving EGFR-TKIs and conventionally fractionated TRT concurrently. Patients receiving both EGFR-TKIs and once-daily TRT were more likely to develop symptomatic RP than patients receiving concurrent chemoradiotherapy.
Curtir
Comentario
Compartilhar
